Write-offs By BioNTech's Collaboration Partner Pfizer Significantly Reduced The Company's Gross Profit Share In The Second Quarter And Hence Negatively Influenced Its Revenues For The Three Months Ended June 30, 2023
Portfolio Pulse from Benzinga Newsdesk
BionTech's Q2 gross profit share was significantly reduced due to write-offs by its collaboration partner Pfizer, negatively impacting its revenues for the three months ended June 30, 2023.
August 07, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BionTech's Q2 revenues were negatively impacted due to write-offs by its partner Pfizer.
BionTech's revenues for Q2 were negatively influenced due to write-offs by its collaboration partner Pfizer. This could potentially lead to a decrease in BionTech's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Pfizer's write-offs have negatively impacted the Q2 revenues of its collaboration partner BionTech.
Pfizer's write-offs have negatively influenced BionTech's Q2 revenues. However, the direct impact on Pfizer's own stock price is unclear without additional information on the reasons and scale of the write-offs.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60